银屑病治疗现状与进展

doi:10.35541/cjd.20250262

Abstract

Abstract: 【Abstract】 Psoriasis is an immune-mediated chronic, relapsing, inflammatory, systemic disease. With advances in the understanding of its mechanisms, treatment strategies have evolved from conventional anti-inflammatory and immunosuppressive approaches to precise targeted interventions against specific cytokines or inflammatory pathways, markedly improving therapeutic efficacy and safety. This article comprehensively reviews the current landscape of psoriasis management and discusses the advancements and emerging trends based on clinical evidence.

Key words: Psoriasis, Molecular targeted therapy, External application drugs, Biological agent, Current status and progress

Sun Qing. Therapeutic strategies for psoriasis: current status and progress[J]. Chinese Journal of Dermatology, 2025, 58(11): 1003-1008.doi:10.35541/cjd.20250262

References ［47］

［1］	Parisi R, Iskandar I, Kontopantelis E, et al. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study［J］. BMJ, 2020,369:m1590. doi: 10.1136/bmj.m1590.
［2］	中华医学会皮肤性病学分会银屑病专业委员会. 中国银屑病诊疗指南（2023版）［J］. 中华皮肤科杂志, 2023,56（7）:573⁃625. doi: 10.35541/cjd.20220839.
［3］	Yélamos O, Puig L. Systemic methotrexate for the treatment of psoriasis［J］. Expert Rev Clin Immunol, 2015,11（5）:553⁃563. doi: 10.1586/1744666X.2015.1026894.
［4］	Paul C, Gallini A, Maza A, et al. Evidence⁃based recommendations on conventional systemic treatments in psoriasis: systematic review and expert opinion of a panel of dermatologists［J］. J Eur Acad Dermatol Venereol, 2011,25 Suppl 2:2⁃11. doi: 10.1111/j.1468⁃3083.2011.03990.x.
［5］	Mariette X, Förger F, Abraham B, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study［J］. Ann Rheum Dis, 2018,77（2）:228⁃233. doi: 10.1136/annrheumdis⁃ 2017⁃212196.
［6］	Hillary T, Lovegrove F, Boye T, et al. Certolizumab pegol for plaque psoriasis in women of childbearing potential, pregnant or breastfeeding in clinical settings: one⁃year outcomes from the international noninterventional CIMREAL study［J］. J Eur Acad Dermatol Venereol, 2025,39（6）:e532⁃e536. doi: 10.1111/jdv. 20516.
［7］	Phan DB, Elyoussfi S, Stevenson M, et al. Biosimilars for the treatment of psoriasis: a systematic review of clinical trials and observational studies［J］. JAMA Dermatol, 2023,159（7）:763⁃771. doi: 10.1001/jamadermatol.2023.1338.
［8］	Phan DB, Yiu ZZ. Biosimilars for the treatment of psoriasis: a narrative review［J］. Ital J Dermatol Venerol, 2024,159（6）:663⁃675. doi: 10.23736/S2784⁃8671.24.08083⁃6.
［9］	Reich K, Armstrong AW, Langley RG, et al. Guselkumab versus secukinumab for the treatment of moderate⁃to⁃severe psoriasis （ECLIPSE）: results from a phase 3, randomised controlled trial［J］. Lancet, 2019,394（10201）:831⁃839. doi: 10.1016/S0140⁃6736（19）31773⁃8.
［10］	Gisondi P, Bellinato F, Galeone C, et al. Risk of developing psoriatic arthritis in patients with psoriasis initiating treatment with different classes of biologics［J］. Ann Rheum Dis, 2025,84（3）:435⁃441. doi: 10.1016/j.ard.2025.01.006.
［11］	Gordon KB, Foley P, Krueger JG, et al. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis （BE READY）: a multicentre, double⁃blind, placebo⁃controlled, randomised withdrawal phase 3 trial［J］. Lancet, 2021,397（10273）:475⁃486. doi: 10.1016/S0140⁃6736（21）00126⁃4.
［12］	Merola JF, Landewé R, McInnes IB, et al. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor⁃α inhibitors: a randomised, double⁃blind, placebo⁃controlled, phase 3 trial （BE COMPLETE）［J］. Lancet, 2023,401（10370）:38⁃48. doi: 10. 1016/S0140⁃6736（22）02303⁃0.
［13］	Morita A, Strober B, Burden AD, et al. Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares （Effisayil 2）: an international, multicentre, randomised, placebo⁃controlled trial［J］. Lancet, 2023,402（10412）:1541⁃1551. doi: 10.1016/S0140⁃6736（23）01378⁃8.
［14］	Strober B, Thaçi D, Sofen H, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52⁃week, randomized, double⁃blinded, phase 3 program for evaluation of TYK2 inhibitor psoriasis second trial［J］. J Am Acad Dermatol, 2023,88（1）:40⁃51. doi: 10.1016/j.jaad.2022.08.061.
［15］	McInnes IB, Anderson JK, Magrey M, et al. Trial of upadacitinib and adalimumab for psoriatic arthritis［J］. N Engl J Med, 2021,384（13）:1227⁃1239. doi: 10.1056/NEJMoa2022516.
［16］	Keam SJ. Tapinarof cream 1%: first approval［J］. Drugs, 2022,82（11）:1221⁃1228. doi: 10.1007/s40265⁃022⁃01748⁃6.
［17］	Papp KA, Weinberg MA, Morris A, et al. IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo⁃controlled, phase 2b study［J］. Lancet, 2021,397（10284）:1564⁃1575. doi: 10.1016/S0140⁃6736（21）00440⁃2.
［18］	Reich K, Cullen E, Weinberg M. Maintenance of response in moderate⁃to⁃severe psoriasis after withdrawal of the interleukin （IL）⁃17A and IL⁃17F nanobody sonelokimab: is there a role for IL⁃17F in disease reoccurrence?［J］. Br J Dermatol, 2022,187（4）:591⁃593. doi: 10.1111/bjd.21617.
［19］	Kim D, Yang S, Gill M, et al. Next⁃generation anti⁃IL⁃17 agents for psoriatic disease: a pipeline review［J］. Am J Clin Dermatol, 2025,26（3）:307⁃320. doi: 10.1007/s40257⁃025⁃00928⁃w.
［20］	Gerdes S, Staubach P, Dirschka T, et al. Izokibep for the treatment of moderate⁃to⁃severe plaque psoriasis: a phase Ⅱ, randomized, placebo⁃controlled, double⁃blind, dose⁃finding multicentre study including long⁃term treatment［J］. Br J Dermatol, 2023,189（4）:381⁃391. doi: 10.1093/bjd/ljad186.
［21］	Warren RB, Reich A, Kaszuba A, et al. Imsidolimab, an anti⁃interleukin⁃36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis: results from the phaseⅡ GALLOP trial［J］. Br J Dermatol, 2023,189（2）:161⁃169. doi: 10.1093/bjd/ljad083.
［22］	A phase 3 multicenter, randomized, double⁃blind, placebo⁃controlled study to evaluate the efficacy and safety of JNJ⁃77242113 for the treatment of participants with moderate to severe plaque psoriasis with randomized withdrawal and retreatment［DB/OL］. （2025⁃04⁃25）［2025⁃05⁃05］. https://clinicaltrials.gov/study/NCT06095115.
［23］	Warren RB, French LE, Blauvelt A, et al. Orismilast in moderate⁃to⁃severe psoriasis: efficacy and safety from a 16⁃week, randomized, double⁃blinded, placebo⁃controlled, dose⁃finding, and phase 2b trial （IASOS）［J］. J Am Acad Dermatol, 2024,90（3）:494⁃503. doi: 10.1016/j.jaad.2023.11.005.
［24］	Warren RB, Strober B, Silverberg JI, et al. Oral orismilast: efficacy and safety in moderate⁃to⁃severe psoriasis and development of modified release tablets［J］. J Eur Acad Dermatol Venereol, 2023,37（4）:711⁃720. doi: 10.1111/jdv.18812.
［25］	Gyldenløve M, Meteran H, Sørensen JA, et al. Efficacy and safety of oral roflumilast for moderate⁃to⁃severe psoriasis⁃a randomized controlled trial （PSORRO）［J］. Lancet Reg Health Eur, 2023,30:100639. doi: 10.1016/j.lanepe.2023.100639.
［26］	Gyldenløve M, Sørensen JA, Fage S, et al. Effects of oral roflumilast therapy on body weight and cardiometabolic parameters in patients with psoriasis ⁃ results from a randomized controlled trial （PSORRO）［J］. J Am Acad Dermatol, 2024,91（1）:64⁃71. doi: 10.1016/j.jaad.2024.02.036.
［27］	Armstrong AW, Gooderham M, Lynde C, et al. Tyrosine kinase 2 inhibition with zasocitinib （TAK⁃279） in psoriasis: a randomized clinical trial［J］. JAMA Dermatol, 2024,160（10）:1066⁃1074. doi: 10.1001/jamadermatol.2024.2701.
［28］	Forman SB, Pariser DM, Poulin Y, et al. TYK2/JAK1 inhibitor PF⁃06700841 in patients with plaque psoriasis: phase iia, randomized, double⁃blind, placebo⁃controlled trial［J］. J Invest Dermatol, 2020,140（12）:2359⁃2370.doi: 10.1016/j.jid. 2020. 03.962.
［29］	Mease P, Helliwell P, Silwinska⁃Stanczyk P, et al. Efficacy and safety of the TYK2/JAK1 inhibitor brepocitinib for active psoriatic arthritis: a phase ⅡB randomized controlled trial［J］. Arthritis Rheumatol, 2023,75（8）:1370⁃1380. doi: 10.1002/art. 42519.
［30］	Papp KA, Beyska⁃Rizova S, Gantcheva ML, et al. Efficacy and safety of piclidenoson in plaque psoriasis: results from a randomized phase 3 clinical trial （COMFORT⁃1）［J］. J Eur Acad Dermatol Venereol, 2024,38（6）:1112⁃1120. doi: 10.1111/jdv.19811.
［31］	A phase 2, international, multicenter, randomized, double⁃blind, placebo⁃controlled, dose⁃ranging study of efficacy and safety of SAR441566 in adults with moderate to severe plaque psoriasis ［DB/OL］. （2025⁃01⁃23）［2025⁃05⁃05］. https://clinicaltrials.gov/study/NCT06073119.
［32］	A Phase 2, multicenter, randomized, double⁃blind, placebo⁃controlled, parallel⁃group, dose ranging study of LY4100511 （DC⁃853） for the treatment of adult participants with moderate⁃to severe plaque psoriasis［DB/OL］. （2025⁃04⁃17）［2025⁃05⁃05］. https://clinicaltrials.gov/study/NCT06602219.
［33］	A randomized, double⁃blind, placebo⁃controlled study to assess the efficacy and safety of SCD⁃044 in the treatment of moderate to severe plaque psoriasis［DB/OL］. （2025⁃04⁃23）［2025⁃05⁃05］. https://clinicaltrials.gov/study/NCT04566666.
［34］	Hashim PW, Chima M, Kim HJ, et al. Crisaborole 2% ointment for the treatment of intertriginous, anogenital, and facial psoriasis: a double⁃blind, randomized, vehicle⁃controlled trial［J］. J Am Acad Dermatol, 2020,82（2）:360⁃365. doi: 10.1016/j.jaad.2019.06.1288.
［35］	Lebwohl MG, Kircik LH, Moore AY, et al. Effect of roflumilast cream vs vehicle cream on chronic plaque psoriasis: the DERMIS⁃1 and DERMIS⁃2 randomized clinical trials［J］. JAMA, 2022,328（11）:1073⁃1084. doi: 10.1001/jama.2022.15632.
［36］	Lebwohl MG, Papp KA, Stein Gold L, et al. Trial of roflumilast cream for chronic plaque psoriasis［J］. N Engl J Med, 2020,383（3）:229⁃239. doi: 10.1056/NEJMoa2000073.
［37］	Kircik LH, Alonso⁃Llamazares J, Bhatia N, et al. Once⁃daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double⁃blind, vehicle⁃controlled phase Ⅱb study［J］. Br J Dermatol, 2023,189（4）:392⁃399. doi: 10.1093/bjd/ljad182.
［38］	Zhu Y, Zhou Y, Ma X, et al. Topical therapy in psoriasis: clinical benefits, advances in novel drug delivery strategies, and gene therapy regimen［J］. Pharmaceutics, 2025,17（3）:283. doi: 10. 3390/pharmaceutics17030283.
［39］	Lin CY, Lin ZC, Chang YT, et al. Novel strategies in topical delivery for psoriasis treatment: nanocarriers and energy⁃driven approaches［J］. Expert Opin Drug Deliv, 2025,22（4）:565⁃581. doi: 10.1080/17425247.2025.2472968.
［40］	Zhang Y, Zang C, Mao M, et al. Advances in RNA therapy for the treatment of autoimmune diseases［J］. Autoimmun Rev, 2025,24（4）:103753. doi: 10.1016/j.autrev.2025.103753.
［41］	Lwin SM, Snowden JA, Griffiths C. The promise and challenges of cell therapy for psoriasis［J］. Br J Dermatol, 2021,185（5）:887⁃898. doi: 10.1111/bjd.20517.
［42］	Cheng L, Wang S, Peng C, et al. Human umbilical cord mesenchymal stem cells for psoriasis: a phase 1/2a, single⁃arm study［J］. Signal Transduct Target Ther, 2022,7（1）:263. doi: 10.1038/s41392⁃022⁃01059⁃y.
［43］	Qiao Z, Zhao W, Liu Y, et al. Low⁃dose interleukin⁃2 for psoriasis therapy based on the regulation of Th17/Treg cell balance in peripheral blood［J］. Inflammation, 2023,46（6）:2359⁃2373. doi: 10.1007/s10753⁃023⁃01883⁃6.
［44］	Dand N, Stuart PE, Bowes J, et al. GWAS meta⁃analysis of psoriasis identifies new susceptibility alleles impacting disease mechanisms and therapeutic targets［J］. Nat Commun, 2025,16（1）:2051. doi: 10.1038/s41467⁃025⁃56719⁃8.
［45］	Nussbaum L, Chen YL, Ogg GS. Role of regulatory T cells in psoriasis pathogenesis and treatment［J］. Br J Dermatol, 2021,184（1）:14⁃24. doi: 10.1111/bjd.19380.
［46］	Eyerich K, Krueger J, Stahle M, et al. An international Delphi consensus to define a clinically appropriate definition of disease modification for plaque psoriasis［J］. J Eur Acad Dermatol Venereol, 2024,38（5）:e424⁃e427. doi: 10.1111/jdv.19652.
［47］	Lwin SM, Azrielant S, He J, et al. Curing psoriasis［J］. J Invest Dermatol, 2024,144（12）:2645⁃2649. doi: 10.1016/j.jid.2024. 09.012.

[1]	Wei Ran, Li Qinfeng. Novel targeted drugs for the treatment of pediatric alopecia areata [J]. Chinese Journal of Dermatology, 2025, 58(7): 650-653.
[2]	Li Xiangqian, Zhang Jianzhong, Zhou Cheng. Advances in the clinical research on systemic small-molecule drugs and biologics for the treatment of alopecia areata [J]. Chinese Journal of Dermatology, 2025, 58(7): 646-649.
[3]	Bai Lu, Chu Yan, Liu Yuanyuan, Zhu Caiyong. Treatment of chronic hand eczema [J]. Chinese Journal of Dermatology, 2025, 58(5): 477-480.
[4]	Committee on Psoriasis, Chinese Society of Dermatology. Expert proposal on apremilast for the treatment of psoriasis （2025 edition） [J]. Chinese Journal of Dermatology, 2025, 58(5): 416-424.
[5]	China Dermatologist Association, Treatment Group, Chinese Society of Dermatology, Dermatology Branch of China International Exchange and Promotive Association for Medical and Health Care, National Clinical Research Center for Dermatologic and Immunologic Diseases, Rare Skin Diseases Committee, China Alliance for Rare Diseases. Diagnosis and treatment of bullous pemphigoid: an expert consensus statement （2025 edition） [J]. Chinese Journal of Dermatology, 2025, 58(5): 405-415.
[6]	Li Ziyu, Lu Yan. Paying attention to severe skin diseases after COVID-19 [J]. Chinese Journal of Dermatology, 2025, 58(4): 378-383.
[7]	Group on Pediatric Dermatology, China Dermatologist Association, Committee on Psoriasis, Chinese Society of Dermatology. Expert consensus on the diagnosis and treatment of pediatric pustular psoriasis in China （2025 version） [J]. Chinese Journal of Dermatology, 2025, 58(4): 297-306.
[8]	He Chunxia, Jin Hongzhong . Principles, current status, challenges and perspectives in the diagnosis and treatment of critical dermatological emergencies [J]. Chinese Journal of Dermatology, 2025, 58(4): 307-314.
[9]	Mu Kui, Guo Hui, Wen Haiquan, Long Hai, Liu Yu, Luo Shuaihantian, Huang Xin, Zhou Xingyu, Xiao Rong, Li Yaping. Efficacy and safety analysis of combined telitacicept in 25 patients with systemic lupus erythematosus based on standard therapy [J]. Chinese Journal of Dermatology, 2025, 58(4): 322-327.
[10]	Li Xiuzhen, Xu Xiulian. Effects of interleukin-23 inhibitors on psoriasis comorbidities [J]. Chinese Journal of Dermatology, 2025, 58(3): 268-272.
[11]	Lianghong Chen Yan SUN Jing-Yu WANG. Benvitimod for the treatment of dermatoses [J]. Chinese Journal of Dermatology, 2025, 58(3): 266-268.
[12]	Huang Shudai, Zhou Xuyue, Zhang Jiaan, Chen Kun. Role of specialized pro-resolving mediators in psoriasis [J]. Chinese Journal of Dermatology, 2025, 0(3): 20240503-e0240503.
[13]	Jin Zhe, Gao Dong. Application and prospect of exosomes in infection and inflammatory skin diseases [J]. Chinese Journal of Dermatology, 2025, 0(3): 20240148-e20240148.
[14]	Zhang Liangliang, Zhang Jiaan, Chen kun . Pathogenesis and treatment of scalp psoriasis [J]. Chinese Journal of Dermatology, 2025, 0(3): 20240001-e20240001.
[15]	Wang Caixia, Xu Fan, Shi Jing, Zhu Hailian, Lu Guiling, Wang Hongmei. Efficacy and safety of omalizumab and dupilumab for the treatment of bullous pemphigoid: a systematic review [J]. Chinese Journal of Dermatology, 2025, 0(3): 20220929-e0220929.

Therapeutic strategies for psoriasis: current status and progress

PDF

Knowledge

Abstract

Cite this article

share this article

References ［47］

Related Articles 15

Metrics

Comments

Recommended 10